Company Profile
Intensity Therapeutics Stock Price, News & Catalysts
- Ticker:
- INTS
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
4.15 USD (+4.80%)
Close
Last updated: August 17, 2026
11.6M USD
Market cap
Why the stock is moving
As of Aug 17, 2026, INTS closed up 4.80% at $4.15. No new same-company headline was identified in the current news window.
Company overview
Intratumoral Cancer Therapy
Intensity Therapeutics develops medicines administered directly into tumors. Its approach is designed to kill injected tumor cells, expose tumor antigens, and stimulate a broader immune response.
INT230-6
INT230-6 combines cytotoxic agents with a proprietary dispersion molecule intended to improve penetration throughout solid tumors. The candidate is being studied both before surgery and in advanced disease.
Soft-Tissue Sarcoma
The Phase 3 INVINCIBLE-3 study evaluates INT230-6 as second- or third-line monotherapy against standard of care in soft-tissue sarcoma, with overall survival as the primary outcome.
Triple-Negative Breast Cancer
The Phase 2 INVINCIBLE-4 study evaluates presurgical INT230-6 followed by standard immunochemotherapy against standard treatment alone in triple-negative breast cancer.
Future catalysts
- Resumption of patient enrollment at a limited number of U.S. sites in the Phase 3 INVINCIBLE-3 study by the third quarter of 2026.
- Completion of enrollment in the Phase 2 INVINCIBLE-4 study by the end of 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Intensity Therapeutics (INTS)?
Intensity Therapeutics (INTS) most recently closed at 4.15 USD, a +4.80% move versus the previous session.
What is the market cap of Intensity Therapeutics (INTS)?
Intensity Therapeutics currently has a market capitalization of 11.6M USD on BioPharmSignal.
What does Intensity Therapeutics do?
Intratumoral Cancer Therapy Intensity Therapeutics develops medicines administered directly into tumors. Its approach is designed to kill injected tumor cells, expose tumor antigens, and stimulate a broader immune response. INT230-6 INT230-6 combines cytotoxic agents with a proprietary dispersion molecule intended to improve penetration throughout solid...
On which exchange is INTS stock listed?
Intensity Therapeutics (INTS) is associated with NASDAQ, United States, Biopharma.
What is INVINCIBLE-3?
sites in the Phase 3 INVINCIBLE-3 study by the third quarter of 2026.
Which conditions is Intensity Therapeutics targeting with INVINCIBLE-3?
Intensity Therapeutics is associated with cancer therapeutics based on its company overview and current catalyst commentary.
How does Intensity Therapeutics describe recent progress with INVINCIBLE-3?
sites in the Phase 3 INVINCIBLE-3 study by the third quarter of 2026.
What is INVINCIBLE-4?
Triple-Negative Breast Cancer The Phase 2 INVINCIBLE-4 study evaluates presurgical INT230-6 followed by standard immunochemotherapy against standard treatment alone in triple-negative breast cancer.